GSK-4112

Chemical compound From Wikipedia, the free encyclopedia

GSK-4112 is an experimental drug that was developed by GlaxoSmithKline as an agonist of Rev-ErbAα.[1] It is used for studying regulation of the circadian rhythm and its influence on diverse processes such as adipogenesis,[2][3] regulation of bone density,[4] and inflammation.[5][6][7][8]

CAS Number
Quick facts Identifiers, CAS Number ...
GSK-4112
Identifiers
  • tert-butyl 2-[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]acetate
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H21ClN2O4S
Molar mass396.89 g·mol−1
3D model (JSmol)
  • CC(C)(C)OC(=O)CN(CC1=CC=C(C=C1)Cl)CC2=CC=C(S2)[N+](=O)[O-]
  • InChI=1S/C18H21ClN2O4S/c1-18(2,3)25-17(22)12-20(10-13-4-6-14(19)7-5-13)11-15-8-9-16(26-15)21(23)24/h4-9H,10-12H2,1-3H3
  • Key:WYSLOKHVFKLWOU-UHFFFAOYSA-N
Close

See also

References

Related Articles

Wikiwand AI